Question of the Day: 4/27/13 Isn't IACP in fact correct that this bill will cause more confusion and blur the jurisdictional line?

IACP 'think[s] the term “compounding manufacturer” and several of the definitions of that new category create more confusion and further blur the jurisdictional authority of regulators."  Isn't IACP     in fact correct that this bill will cause more confusion and blur the jurisdictional line?  Won't this bill in fact cause more court litigation over these definitions, the jurisdiction and who in fact fits within these definitions and falls under the FDA's jurisdiction?